Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5697
Source ID: NCT01131052
Associated Drug: Insulin Glargine
Title: Diabetes in the Elderly: Prospective Study
Acronym: DMElderly
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT01131052/results
Conditions: Diabetes|Hyperglycemia
Interventions: DRUG: Insulin Glargine|DRUG: Insulin|DRUG: Insulin glulisine
Outcome Measures: Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL, Mean weekly blood glucose concentration less than 70 mg/dL at 3 months, 3 months|Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL, Mean weekly blood glucose concentration less than 40 mg/dL at 3 months, 3 months|Mean of Weekly Fasting Blood Glucose Concentration, Mean weekly blood glucose concentration at 3 months, 3 months | Secondary: Mean Blood Glucose Concentration, Mean blood glucose concentration at baseline, Baseline|Mean of Glycosylated Hemoglobin (hbA1c), Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent., Baseline|Mean of Daily Blood Glucose Concentration, Mean of daily blood glucose concentration at baseline, Baseline|Mean of Glycosylated Hemoglobin (hbA1c), Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent., 3 months|Mean of Glycosylated Hemoglobin (hbA1c), Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent., 6 months
Sponsor/Collaborators: Sponsor: Guillermo Umpierrez
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 150
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2011-03
Completion Date: 2013-12
Results First Posted: 2014-12-31
Last Update Posted: 2014-12-31
Locations: Guillermo Umpierrez, Atlanta, Georgia, 30303, United States
URL: https://clinicaltrials.gov/show/NCT01131052